What is the Bionet Therapeutics Corp. stock price forecast?

Bionet Therapeutics Corp. is currently trading at $38.00. View real-time AI analysis on Alpha Lenz.

What is Bionet Therapeutics Corp. insider trading activity?

View the latest insider trading data for Bionet Therapeutics Corp. on Alpha Lenz.

What is Bionet Therapeutics Corp.'s P/E ratio?

View Bionet Therapeutics Corp.'s valuation metrics on Alpha Lenz.

Bionet Therapeutics Corp.

TWSE · 7808

NT$38.00+0.05(+0.13%)

Ask about Bionet Therapeutics Corp.'s future dividend policy...

Alpha Chat Insight

“Bionet Therapeutics Corp.'s ROE is -7.8%. Explore profitability and growth together.”

Ask for details →

Company Overview

Bionet Therapeutics Corp. is a biotechnology company specializing in the research, development, and manufacture of advanced cell therapies and regenerative medical products. Founded in 2022 and headquartered in Taipei, the company focuses on innovative solutions for severe and chronic medical conditions, such as acute respiratory distress syndrome, pulmonary fibrosis, chronic kidney failure, diabetic ulcers, degenerative arthritis, and dry eye syndrome. Bionet Therapeutics applies proprietary cell therapy technologies and operates a mesenchymal stem cell bank, servicing both clinical and commercial applications in regenerative medicine. In addition to its clinical pipeline, the company provides CRDMO (Contract Research, Development, and Manufacturing Organization) services and develops exosome-based products, which include both therapeutics and commercialized skin care applications. Bionet Therapeutics Corp. plays a significant role in Taiwan’s biopharmaceutical sector, contributing to the advancement of cell and gene therapies and supporting the integration of precision health services across the medical field.

CEODr. Cheng-Hsien Tsai

Websitehttps://www.bionettx.com

SectorHealthcare

IndustryBiotechnology

Employees73

Company Statistics

FY 2025

Profile

N/AMarket Cap

NT$154.48MRevenue

0.00Shares Out

73Employees

Margins

39.91%Gross

-55.39%EBITDA

-75.37%Operating

-63.07%Pre-Tax

-63.07%Net

Valuation

N/AP/E

N/AP/B

N/AEV/Sales

N/AEV/EBITDA

N/AP/FCF

Growth (CAGR)

N/ARev 3Yr

N/ARev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-7.40%ROA

-7.76%ROE

-7.39%ROIC

Financial Health

NT$99.52MCash & Cash Equivalents

NT$-31.87MNet Debt

5.57%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Bionet Therapeutics Corp.'s ROE is -7.8%. Explore profitability and growth together.”

Ask for details →

Frequently Asked Questions

Bionet Therapeutics Corp. (ticker: 7808) is a company listed on TWSE in the Healthcare sector (Biotechnology). It has approximately 73 employees.

The current price is 38 with a P/E ratio of -x and P/B of -x.

ROE is -7.76% and operating margin is -75.37%. Annual revenue is $154M.